Davis Polk advised ViewRay, Inc. in a direct-registered offering of 7,090,581 shares of ViewRay’s common stock and 1,418,116 warrants to purchase shares of ViewRay’s common stock for proceeds to ViewRay of approximately $59 million. ViewRay’s common stock is listed on the NASDAQ Global Market under the symbol “VRAY.”
Headquartered in Oakwood Village, Ohio, ViewRay designs, manufactures and markets the first and only MRI-guided radiation therapy system that simultaneously images and treats cancer patients, called MRIdian.
The Davis Polk capital markets team included partner Alan F. Denenberg and associates Jeffrey C. Lau, Amy Tu and Dylan Service. All members of the Davis Polk team are based in the Northern California office.